Skip to main content

Frank Laukien, Martin Haase, Laura Francis, John Hulburt, Michael Willett, Rajen Dalal, Joseph Limber, Michael Witt


Bruker Daltonics of Billerica, Mass., and Bruker AXS of Madison, Wis., announced their intention to merge last week (see article p.1). The new company, to be called Bruker BioSciences, is to be led by president and CEO Frank Laukien, who currently holds these positions at Bruker Daltonics. Martin Haase, CEO of Bruker AXS, is to become senior vice president. Laura Francis, CFO of Bruker AXS, is designated as the new company’s CFO and treasurer. John Hulburt, Bruker Daltonics’ CFO, is slated to become director of audit and SEC compliance. Michael Willett, investor relations officer at Bruker Daltonics, would retain this position at Bruker BioSciences.


Rajen Dalal, president and CEO of Guava Technologies, has become a member of the board of directors of Fremont, Calif.-based Ciphergen Biosystems. Prior to joining Guava last year, he spent ten years at Chiron, where he was president of the blood testing division. Before, he led pharmaceuticals and technology management groups at McKinsey & Co. Rajen has a bachelor’s degree in chemistry from St. Xavier’s College at the University of Bombay, a master’s in biochemical engineering from MIT, and an MBA from the University of Chicago.


Joseph Limber has become interim CEO of Redwood City, Calif.-based Deltagen. He will move on to become president and CEO once the company has closed its financing round. Until 2002, Limber was president and CEO of Aclara Biosciences. Prior to that, he was president and COO of Praecis Pharmaceuticals. Limber holds a BA from Duquesne University.


Michael Witt has become executive director of MichBio, Michigan’s biosciences industry association. Prior to his appointment, he was CEO of Technology Enterprise Development, a medical technology development company, and CEO of, a healthcare information and software company. Witt holds a PharmD from the University of California, San Francisco School of Pharmacy and a JD from Case Western Reserve University School of Law.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.